Compare AbbVie Inc (ABBV) vs Manulife Financial Corporation (MFC) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Manulife Financial (MFC) trades at $44.32, down 0.58% with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results with double-digit growth in Asia and insurance sales, beating EPS expectations. Revenue reached $53.01B in 2025 with net income of $5.78B, though profit margins have moderated from 2022 peaks. Analysts maintain a Moderate Buy consensus with 57% buy ratings.

MFC presents a positive investment case with solid earnings growth, expanding Asian operations, and consistent dividend payments. However, premium valuation metrics and moderating profit margins warrant caution. The stock faces risks from wealth management outflows and competitive pressures in core markets, requiring careful monitoring of Q3 earnings performance.